 AGOURA HILLS, Calif., Feb. 24, 2022 GLOBE NEWSWIRE -- Oncotelic Therapeutics, Inc. Oncotelic or the Company OTCQB:OTLC , a leading developer of TGF-β therapeutics for oncology and virology, today announced that Dr. Vuong Trieu, Oncotelic Chairman and CEO, will be presenting at MedInvest Pharmaceutical and Biotechnology Investor Conference the Conference, from March 28 - April 1, 2022. 